Origenis beruft Thomas Loeser zum Chief Financial Officer
Martinsried, Germany, March 15, 2018 - Origenis GmbH, a German biotech company
specializing in the discovery and development of highly selective small molecule kinase
inhibitors for CNS disorders, today announced the appointment of Thomas Loeser as Chief
Financial Officer (CFO).
Thomas has 30 years of European / U.S. capital market expertise with a particular focus on
financing technological innovation and on managing growth and value creation by crossborder
team building and transatlantic company development strategies.
Since 1998, he has managed several German, Swiss and U.S. biotechnology companies
through rapid growth and difficult market cycles. His range of responsibilities included
fundraising, corporate finance/governance, legal and HR functions, transatlantic M&A,
business development and dealmaking for strategic planning.
Among others, his CFO duties included the fundraising and company development strategy
of ESBATech AG, a Zurich-based biotechnology company, that resulted in the uplift to the
Nr. 1 position of Switzerland´s 2006 list of “Top 50 Growth Companies” and the closing of a
large Preferred Series B round led by a reknowned U.S. syndicate. Further, the execution of
a transatlantic company development strategy resulted in the acquisition of the Company´s
ophthalmology portfolio by Alcon, Inc., in 2009 and the demerger of all other assets into
Delenex Therapeutics AG, that in 2017 were acquired by Cell Medica Ltd.
Origenis´CEO Michael Almstetter commented: “We are delighted to expand our executive
management team with Thomas. With his proven track record in fundraising, M&A and exits,
he brings in a sound understanding of capital markets and an established network of high
caliber relationships with institutional investors and investment banks, particularly in the U.S.
As we have an upcoming financing round ahead of us, we are very confident that Thomas
will help us to steer Origenis in a successful direction.” -ends-